[go: up one dir, main page]

MX2017017171A - Compuestos terapeuticos y composiciones para el tratamiento de trastornos sociales y trastornos de uso de sustancias. - Google Patents

Compuestos terapeuticos y composiciones para el tratamiento de trastornos sociales y trastornos de uso de sustancias.

Info

Publication number
MX2017017171A
MX2017017171A MX2017017171A MX2017017171A MX2017017171A MX 2017017171 A MX2017017171 A MX 2017017171A MX 2017017171 A MX2017017171 A MX 2017017171A MX 2017017171 A MX2017017171 A MX 2017017171A MX 2017017171 A MX2017017171 A MX 2017017171A
Authority
MX
Mexico
Prior art keywords
disorders
compositions
substance use
therapeutic compounds
treating social
Prior art date
Application number
MX2017017171A
Other languages
English (en)
Other versions
MX389545B (es
Inventor
Kassiou Michael
Stewart Mcgregor Iain
Thomas BOWEN Michael
Hicks Callum
Jorgensen William
Original Assignee
Univ Sydney
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015902659A external-priority patent/AU2015902659A0/en
Application filed by Univ Sydney filed Critical Univ Sydney
Publication of MX2017017171A publication Critical patent/MX2017017171A/es
Publication of MX389545B publication Critical patent/MX389545B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En la presente se describen los compuestos composiciones y métodos para el tratamiento de trastornos neurológicos los cuales están caracterizados por una disrupción fundamental de la conducta social, y los trastornos por abuso de sustancias. En particular, en la presente se describen compuestos de la Fórmula (l) o sales o profármacos de la misma. Los métodos para tratar o prevenir trastornos neurológicos, psiquiátricos y de abuso de sustancias, al utilizar los compuestos de la Fórmula (I) o sales y profármácos también se describen.
MX2017017171A 2015-07-06 2016-07-06 Compuestos terapeuticos y composiciones para el tratamiento de trastornos sociales y trastornos de uso de sustancias. MX389545B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2015902659A AU2015902659A0 (en) 2015-07-06 Therapeutic compounds and compositions for treating social disorders and substance use disorders
PCT/AU2016/050588 WO2017004674A1 (en) 2015-07-06 2016-07-06 Therapeutic compounds and compositions for treating social disorders and substance use disorders

Publications (2)

Publication Number Publication Date
MX2017017171A true MX2017017171A (es) 2018-04-30
MX389545B MX389545B (es) 2025-03-20

Family

ID=57684596

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017017171A MX389545B (es) 2015-07-06 2016-07-06 Compuestos terapeuticos y composiciones para el tratamiento de trastornos sociales y trastornos de uso de sustancias.

Country Status (18)

Country Link
US (3) US11033555B2 (es)
EP (1) EP3328864B1 (es)
JP (2) JP7089825B2 (es)
KR (1) KR102686349B1 (es)
CN (1) CN107922420B (es)
AU (1) AU2016289271B2 (es)
CA (1) CA2991236A1 (es)
DK (1) DK3328864T3 (es)
ES (1) ES2932194T3 (es)
HU (1) HUE060496T2 (es)
IL (1) IL256684B (es)
MX (1) MX389545B (es)
NZ (1) NZ738672A (es)
PL (1) PL3328864T3 (es)
PT (1) PT3328864T (es)
RU (1) RU2715384C2 (es)
SI (1) SI3328864T1 (es)
WO (1) WO2017004674A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102686349B1 (ko) 2015-07-06 2024-07-17 키녹시스 테라퓨틱스 피티와이 리미티드 사회성 장애 및 물질 사용 장애의 치료를 위한 치료 화합물 및 조성물
EP4494705A3 (en) * 2016-12-12 2025-04-02 Kinoxis Therapeutics Pty Ltd Non-peptide oxytocin receptor agonists
AU2019383052A1 (en) * 2018-11-23 2021-06-10 Macquarie University Methods for management of weight
EP4025221A4 (en) * 2019-09-06 2024-01-03 Kinoxis Therapeutics Pty Ltd TREATMENT OF OPIOID WITHDRAWAL
US20240287074A1 (en) * 2020-09-07 2024-08-29 Kinoxis Therapeutics Pty Ltd Salts and crystals
CN116829560A (zh) * 2020-12-14 2023-09-29 金奥克斯治疗有限公司 催产素受体调节剂
MX2023010849A (es) * 2021-03-18 2023-09-21 Kinoxis Therapeutics Pty Ltd Métodos de tratamiento.
CN115677585B (zh) * 2022-10-31 2024-03-19 上海群力化工有限公司 一种甲醛吡唑衍生物的合成工艺
WO2024100791A1 (ja) 2022-11-09 2024-05-16 株式会社日本ファインケム １－アルキル－５－ヒドロキシピラゾールの製造方法
WO2025172368A1 (en) 2024-02-13 2025-08-21 Syngenta Crop Protection Ag (5-isoxazol-3-yl)-[4-(pyrazol-4-yl)-3,4-dihydro-1h-isoquinolin-2-yl]methanone derivatives for use as fungicides
WO2025191053A1 (en) 2024-03-14 2025-09-18 Syngenta Crop Protection Ag Microbiocidal pyrazole derivatives
WO2025210095A1 (en) 2024-04-03 2025-10-09 Syngenta Crop Protection Ag Microbiocidal tetrahydroisoquinoline compounds
CN119386023A (zh) * 2024-10-25 2025-02-07 南方医科大学南方医院 地尔硫卓在制备治疗自闭症的药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0115515D0 (en) * 2001-06-25 2001-08-15 Ferring Bv Oxytocin agonisys
EP1512687A1 (en) * 2003-09-05 2005-03-09 Ferring B.V. Piperazines as oxytocin agonists
EP1632494A1 (en) * 2004-08-24 2006-03-08 Ferring B.V. Vasopressin v1a antagonists
CA2626180A1 (en) 2005-10-24 2007-05-03 Wyeth Tricyclic compounds useful as oxytocin receptor agonists
GB0903493D0 (en) * 2009-02-27 2009-04-08 Vantia Ltd New compounds
EP2571360A4 (en) 2010-05-19 2013-07-31 Univ North Carolina METHOD AND FORMULATIONS FOR OXYTOCIN TREATMENT OF DRUG ABUSE AND PSYCHIATRIC AND OTHER DISORDERS
GB201015371D0 (en) 2010-09-14 2010-10-27 Optinose As Nasal delivery
KR20140124465A (ko) 2013-04-17 2014-10-27 인제대학교 산학협력단 사회 정서 관련 행동 조절을 위한 비강용 옥시토신의 용도
KR102686349B1 (ko) 2015-07-06 2024-07-17 키녹시스 테라퓨틱스 피티와이 리미티드 사회성 장애 및 물질 사용 장애의 치료를 위한 치료 화합물 및 조성물
EP4025221A4 (en) 2019-09-06 2024-01-03 Kinoxis Therapeutics Pty Ltd TREATMENT OF OPIOID WITHDRAWAL
MX2023010849A (es) 2021-03-18 2023-09-21 Kinoxis Therapeutics Pty Ltd Métodos de tratamiento.

Also Published As

Publication number Publication date
RU2715384C2 (ru) 2020-02-27
KR20180023992A (ko) 2018-03-07
BR112018000059A2 (pt) 2018-09-04
US20240245706A1 (en) 2024-07-25
MX389545B (es) 2025-03-20
WO2017004674A1 (en) 2017-01-12
EP3328864B1 (en) 2022-09-07
DK3328864T3 (da) 2022-12-05
NZ738672A (en) 2022-11-25
JP7490018B2 (ja) 2024-05-24
CN107922420B (zh) 2021-12-31
CA2991236A1 (en) 2017-01-12
US12458648B2 (en) 2025-11-04
US11890287B2 (en) 2024-02-06
JP2018525351A (ja) 2018-09-06
IL256684B (en) 2022-06-01
RU2018103873A3 (es) 2019-09-04
HUE060496T2 (hu) 2023-03-28
US20190290658A1 (en) 2019-09-26
JP7089825B2 (ja) 2022-06-23
AU2016289271A1 (en) 2018-01-25
RU2018103873A (ru) 2019-08-06
JP2022130418A (ja) 2022-09-06
PT3328864T (pt) 2022-12-07
EP3328864A4 (en) 2019-01-09
IL256684A (en) 2018-03-29
US20220362261A1 (en) 2022-11-17
ES2932194T3 (es) 2023-01-16
SI3328864T1 (sl) 2023-02-28
HK1252813A1 (zh) 2019-06-06
AU2016289271B2 (en) 2020-12-03
CN107922420A (zh) 2018-04-17
KR102686349B1 (ko) 2024-07-17
PL3328864T3 (pl) 2023-02-27
EP3328864A1 (en) 2018-06-06
US11033555B2 (en) 2021-06-15

Similar Documents

Publication Publication Date Title
MX2017017171A (es) Compuestos terapeuticos y composiciones para el tratamiento de trastornos sociales y trastornos de uso de sustancias.
ZA202001717B (en) Compounds, salts thereof and methods for treatment of diseases
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
MX2018000396A (es) Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4).
PH12018500040A1 (en) Indazole and azaindazole compounds as irak-4 inhibitors
MX2021008281A (es) Estimuladores de guanilato ciclasa soluble (sgc).
PH12019500196A1 (en) Compounds and compositions and uses thereof
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
MX392026B (es) Compuestos heterocíclicos como inmunomoduladores.
MY202022A (en) Pyrrolotriazine compounds as tam inhibitors
MX2018006223A (es) Moduladores de ror-gamma.
TN2017000075A1 (en) Compounds and compositions as raf kinase inhibitors
MX2017004618A (es) Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades.
MY194341A (en) Method of treating a brain tumor
PH12017500653A1 (en) Substituted benzothiophenyl derivatives as gpr40 agonists for the treatment of type ii diabetes
MX2016011105A (es) Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos.
TW201613878A (en) Pyrazine GPR40 agonists for the treatment of type II diabetes
PH12019500198A1 (en) Compounds and compositions and uses thereof
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
MX2022006229A (es) Composiciones y metodos para el tratamiento de resistencia a la insulina.
MX2018007517A (es) Compuestos triciclicos y composiciones como inhibidores de quinasa.
BR112017007916A2 (pt) compostos sarms para tratamento de distúrbios urológicos
MX2019000608A (es) Derivados de panteteina para tratamiento de trastornos neurologicos.
WO2019040104A3 (en) COMPOUNDS, RELATED SALTS AND METHODS OF TREATING DISEASES
NZ750581A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy